Purpose: Serotonin is a key regulatory neurotransmitter in the CNS which plays an important role in seizure through different receptors, especially the 5HT 1A subtype. The role of sertraline through the 5HT 1A receptor and nitric oxide interaction on the PTZ-induced seizure threshold was investigated in this study. Method: In this study, 70 white male mice were randomly divided into 10 groups including intact control, sham-control and eight experimental groups which received sertraline, 8-OH-DPAT, WAY100635, WAY100635 + sertraline, WAY100635 + 8-OH-DPAT, L-NAME, L-NAME + sertraline and L-NAME + 8-OH-DPAT. After 14 days of treatment in different groups, the PTZ-induced seizure threshold was assessed and the measurement of nitric oxide metabolites in the brain tissue was done with the Greiss method. Results: The seizure threshold was significantly increased in the sertraline and 8OH-DPAT receiving groups compared to the sham group (P < 0.001). In the presence of WAY100635, the effect of both sertraline and 8-OH-DPAT in raising the seizure threshold was more prominent (P < 0.001) but on the other hand, in the presence of L-NAME, an increase in the anticonvulsant effect of 8-OH-DPAT was observed, while L-NAME alone had no effect on the seizure threshold (P < 0.001). The NO X concentrationwas significantly decreased in the 8-OH-DPAT_treated group (P < 0.01), while the WAY100657 reversed it and the combination of 8-OH-DPAT with L-NAME reduced the NO X levels (P < 0.001). Conclusions: These findings support the anticonvulsant effect of SSRIs and selective 5HT 1A receptors, although serotonin receptors other than 5HT 1A subtype may be involved and also it is probable that some anticonvulsant effects of the sertraline and 8-OH-DPAT are through the modulation of nitrergic system.
Introduction
Serotonin or 5-hydroxytryptamine is a monoamine neurotransmitter derived from hydroxylation and decarboxylation of L-tryptophan [1] [2] [3] and can regulate various physiological and behavioral processes [4, 5] . Each type of disturbance in the synthesis, metabolism or reuptake of serotonin may lead to neurological disorders such as migraine, Alzheimer's disease, depression and seizure [6] [7] [8] . Serotonin has seven families of receptors (5HT 1 to 5HT 7 ) that may be involved in different types of seizures [9, 10] . Serotonergic projections which are extensive in the anterior brain and brain stem structures [9] .
Among various subtypes of serotonin receptors (5HT 1 to 5HT 7 ), the 5HT 1A receptor plays an important role in seizures [11] . In the mammalian brain, the 5HT 1A receptor has pre-and post-synaptic distribution [12] . Activation of the 5HT 1A autoreceptor diminishes the activity of serotonergic neurons and thereby decreases the release of serotonin. In contrast, the activity of the postsynaptic 5HT 1A receptors mimics the effects of the serotonin release and facilitates serotonin transmission [13, 14] . Unfortunately in acute seizures with a natural hippocampus, the effect of the 5HT 1A receptor is still controversial [15] . In different seizure models, the 5HT 1A receptor can have exerts anticonvulsant [16, 17] and proconvulsant effects [18] or even it can have a neutral effect [19, 20] on seizure.
Nitric oxide (NO) is synthesized from L-arginine by the nitric oxide synthase (NOS) [21] and plays an important role in the normal action of the brain [22] . Although it has shown its anticonvulsant or proconvulsant properties in different seizure models but its role in seizure is not completely clear [23] .
Recently, the interaction between the 5-HT receptor subtypes and NO has been proposed [21] . Some selective serotonin reuptake inhibitors (SSRIs) such as paroxetine act as an NOS inhibitor [24] . On the other hand, some NOS inhibitors such as L-N G -Nitroarginine methyl ester (L-NAME) have antidepressant effect and boost the effect of SSRIs. The 5HT 1A agonists such as 8-OH-DPAT downregulate nNOS expression and leads to a decrease in NO, an effect which is blocked by application of the 5-HT 1A receptor antagonists. These findings suggest that NO may be a downstream signaling molecule of 5-HT [25] . A model of the 5-HT 1A receptor-nNOS-CREB pathway has been proposed in some studies [24, 25] . In the present study, we examined the effect of chronic administration of sertraline and 8-OH-DPAT on the PTZ-induced clonic seizures threshold in male mice. Regarding the functional interactions of 5HT with NO signaling pathway and the fact that both sertraline and 8-OH-DPAT are the 5HT 1A receptor agonist, we further investigated the possible involvement of NO in the modulatory effect of these compounds on the seizure susceptibility by using L-NAME.
Method
All experiments were performed in accordance with the guide for the Care (25 C) and humidity (%50-60) with a 12 h light and 12 h dark cycle. They were fed standard mouse food with ad libitum access to water. Animals were divided randomly into ten groups (n = 7 in each group) including intact control, sham-control and eight experimental groups which received sertraline, 8-OH-DPAT, WAY100635, WAY100635 + sertraline, WAY100635 + 8-OH-DPAT, L-NAME, L-NAME + sertraline and L-NAME + 8-OH-DPAT.
Chemicals and drugs
The drugs used were PTZ, sertraline, 8-OH-DPAT, WAY100635 and L-NAME. All the above_mentioned drugs except sertraline were purchased from Sigma (USA). Sertraline was purchased from Darupakhsh (Tehran/Iran).
Procedure
PTZ(0.5% solution) was prepared in 0.9% saline and administered as intravenous infusion. In addition, sertraline was prepared at carboxymethylcellulose(CMC, 0.5%) as a solvent agent and administered orally by gavage for 14 days.
Other drugs were dissolved in normal saline solution at desired concentration and administered intraperitoneally (IP), in a volume of 10 ml/kg of body weight.
The doses of sertraline, 8-OH-DPAT, WAY100635 and L-NAME were chosen based on the previous studies and pilot experiments. WAY100635 was injected 30 min before the administration of sertraline or 8-OH-DPAT.
Seizure induction
PTZ was dissolved in heparinized sterile saline (0.9%) to prepare a fresh solution with a concentration of 5 mg/ml before an intravenous (IV) infusion. The dose and infusion rate of the administered PTZ was 5 mg/ml and 0.5 ml/min, respectively [26] . Before testing, each mouse was weighed and placed in a clear acrylic plastic restrainer and then its tail was immersed in a warm water bath (40) (41) (42) (43) (44) (45) C) for 1 min to dilate the tail veins. A dental carpule (30 G) connected by a polyethylene tube (No. 10) to a 10 ml syringe prefilled with heparinized PTZ solution was used. The needle was inserted into the mid length of the lateral tail vein and during the infusion period, the animal could move freely with the aid of attached canula. Each animal was observed throughout the infusion period and the duration time between the start of infusion and onset of clonic seizures was recorded in seconds and converted to the threshold convulsant dosage by the following formula [27] This effect also was potentiated with pre-treatment by WAY100635 in combination with 8-OH-DPAT or sertraline. ***P < 0.001 compared to vehicle. ^^^ P < 0.001 compared to 8-OH-DPAT group. {{{ P < 0.001 compared to sertraline group. ### P < 0.001 compared to WAY100635 group.
Measurement of total nitrate and nitrite (NOx)
The assay described by Miranda et al. [28] was used to reduce nitrate to nitrite by vanadium (III) chloride, followed by the spectrophotometric analysis of total nitrite using Greiss reagent. For the measurement of nitric oxide metabolites in the brain tissue samples, 1 gram of brain tissue was homogenized in 10 ml of Tris Hcl 50 mM, containing 0.1 mM EDTA and the homogenized suspension was deproteinized by trichloroacetic acid (10%) to reduce turbidity. Experiments were performed at room temperature, as noted. A nitrate standard solution (100 ml) was serially diluted (from 20 to 100 mM) in a 96-well microplate. First, plate loaded with samples (100 ml) and VCl3 (100 ml), then sulfanilamide (50 ml) and NEDD (50 ml) were added to each well and at last diluting medium was used to determine blank values. It should be noted that the absorbance at 540 nm was measured by using a plate reader following the incubation (45 min) [29] .
Statistical analysis
All results were expressed as mean values AE SEM. Statistical analysis of the results was done by one-way ANOVA for the seizure thresholds followed by Tukey's test for multiple comparisons. Differences were considered significant if the P value were less than 0.05.
Results
Fig . 1 illustrates the effects of 14 days sertraline (10 mg/kg) or 8-OH-DPAT (1 mg/kg) administration on the PTZ-induced seizure threshold. The clonic seizure threshold was increased significantly in both sertraline and 8-OH-DPAT treated groups compared to the vehicle (P < 0.001). WAY100635, the specific 5HT 1A receptor antagonist (0.3 mg/kg, i.p) alone did not alter the PTZ-induced clonic seizure threshold. Unexpectedly, the combination of WAY100635 (0.3 mg/kg, i.p) with 8-OH-DPAT or sertraline, potentiated the anticonvulsant effect of both drugs. Fig. 2 illustrates the effects of 14 days L-NAME administration (50 mg/kg) alone and in combination with sertraline (30 mg/kg) or 8-OH-DPAT (1 mg/kg). Sub-effective dose of L-NAME (50 mg/kg) failed to show anticonvulsant activity. The co-administration of L-NAME (50 mg/kg) with 8-OH-DPAT (1 mg/kg) significantly increased the PTZ-induced seizure threshold, while the co-administration of L-NAME (50 mg/kg) with sertraline (10 mg/ kg) had no effect on the seizure threshold. Fig. 3 shows the brain tissues concentration of NOx in the L-NAME treated groups. L-NAME at sub-effective concentration (50 mg/kg) significantly decreased the NOx concentration compared to the sham control group (p < 0.01).
The brain tissues concentrations of NOx in 8-OH-DPAT treated group was significantly lower than sham group and the co-administration of sub-effective of L-NAME(50 mg/kg) with 8OH-DPAT(1 mg/kg) further decreased NOx concentration. Sertraline (10 mg/kg) alone or in combination with sub-effective concentration of L-NAME (50 mg/kg) had no significant effect on NOx concentration.
Discussion
In the present study, we investigated the effect of sertraline (a SSRI inhibitor) and 8-OH-DPAT (a specific 5HT 1A receptor antagonist) on the PTZ-induced clonic seizure threshold. The results showed that both sertraline and 8OH-DPAT significantly increased the PTZ-induced clonic seizure threshold in mice.
Some studies indicate that serotonin has a protective effect against epilepsy in the central nervous system and some SSRIs have anticonvulsant effect [30] . Loscher showed that the stimulation of 5HT 1A receptor with SSRIs had protective effects against seizures [31] . Although some studies have shown that the anticonvulsant effect of SSRIs is not solely mediated through the 5HT 1A receptor [32, 33] .
SSRI family has been found to possess antiepileptic properties in human and animal models of epilepsy [34] .
The primary effect of SSRIs is increasing 5HT in the synaptic cleft. The results of animal studies show that 5-HT plays an important role in the neural excitability, epileptogenesis, and seizure propagation [35, 36] . Among the SSRIs, sertraline was selected, because it has the lowest reported seizure occurrence [37] and can be safely used in the vast majority of epileptic patients [38] .
In accordance with the sertraline increased the PTZ-induced seizure threshold in this study, studies showing that agents such as SSRIs have antiepileptic effect through the increase of extracellular 5-HT [11, 39] , just like sertraline, 8OH-DPAT increased the PTZ-induced seizure threshold. The activation of 5HT 1A receptors inhibits adenylyl cyclase and decreases cAMP production. It also Fig. 2 . The effect of chronic pre-treatment with L-NAME alone and in combination of 8-OH-DPAT or sertraline on the seizure threshold. The seizure threshold was significantly increased in pre-treatment with L-NAME in combination with 8-OH-DPAT but this effect was not observed with pre-treatment with L-NAME alone or with L-NAME in combination with sertraline. ***P < 0.001 compared to L-NAME.
activates G protein-coupled potassium channels [40] . Although it is generally believed that the 5HT 1A activation increases the seizure threshold in most of the animal models, some studies have demonstrated that the 5TH 1A agonists such as 8OH-DPAT decrease the seizure threshold [41, 42] . However, our results confirm the findings that show the 5HT 1A have anticonvulsant effect. Of course, it must be noted that 8OH-DPAT has also affinity for other 5HT 7 receptors [19] . WAY100635 (N-[4-2-methoxyphenyl)-1-piperazinyl]-N-(2-pyridinyl)cyclo hexanecarboxamide alone had no effect on the seizure threshold. Interestingly, the co-administration of sertraline or 8-OH-DPAT with WAY-100635 further increased the seizure threshold. Similarly, Manuel-Apolinar et al. [39] reported that 8OH-DPAT increased cAMP in cortex and hippocampus and the coadministration of WAY 100635 with 8OH-DPAT produced higher levels of cAMP in these areas. They proposed a possible link among the 5HT 1A and 5HT 7 receptors, because 8OH-DPAT had affinity to both receptors [39] . Since WAY 100635 is highly selective antagonist for the 5-HT 1A receptor [6] , it is likely that anticonvulsant effect of sertraline and 8OH-DPAT has been potentiated by the involvement of 5HT 7 receptor. These data suggest possible interplay between the 5-HT 1A and 5-HT 7 receptors during anticonvulsant drug action.
In the case of 5HT 7 , both proconvulsant and anticonvulsant effects have been reported [43] [44] [45] . According to the study of Mirski et al., the 5HT 1/5A/7 agonist, 5-CT, increased the PTZinduced seizure threshold in rats [46] and also in 5HT 7 knockout mice, the threshold of PTZ, NMDA, cocaine and electroshockinduced seizures were decreased [44] . Thus, it is likely that the anticonvulsant effect of sertraline and 8OH-DPAT in the presence of WAY100635 has been potentiated through the modulation of 5HT 1A autoreceptors.
The effect of SSRIs partly depends on the 5-HT 1A auto-receptor functions. The 5-HT 7 receptors can also be involved in the therapeutic effects of these drugs. For example, SSRIs induced c-Fos expression in rats. The effect is like the 5-HT 7 receptor activation. Moreover, chronic treatment with SSRIs decreased the 5-HT 7 receptor binding [47] .
The 5HT 1A receptor is widely known as an autoreceptor [40] that reduces the release of serotonin during the treatment with SSRI, and leads to a delay in the onset of therapeutic effects of SSRI. The combination of 5HT 1A receptor antagonist with the SSRI by inhibiting the autoreceptor, maximizes the serotonin levels and strengthens the effect of SSRI [15] . On the other hand, a study has shown that by a dose between 1.0 to 3.0 mg/kg of WAY100635, the somatodendritic 5HT 1A receptors have been blocked [40, 42] . In the present study, this assumption may be made that the 5HT 1A antagonist (WAY100635) with preferential inhibition of autoreceptor, enhances the effect of sertraline through postsynaptic receptors. Then, increase in the amount of extracellular serotonin leads to the increase in the seizure threshold and augment the anticonvulsant effect.
NO is a free radical with signaling functions in the CNS and is mainly produced by neuronal nitric oxide synthase (nNOS) [21] . Based on previous studies, NO has both proconvulsant and anticonvulsant properties [23] . The role of nitrergic system in the central effects of 5HT agonists and SSRIs has been previously described. For example, nNOS-derived NO has been reported to induce antidepressant and anxiolytic effects [48] [49] [50] . In addition, the effects of NO on locomotor activity in the dorsal raphe nucleus is mediated through the 5HT 1A receptors [51] .
In the case of epilepsy, low doses of citalopram had anticonvulsant effect through the 5HT 3 receptors and the combination of L-NAME or 7-NI with citalopram augmented this effect [52] .
In the present study, 14 days pretreatment with 8OH-DPAT, unlike sertraline, was accompanied by lower levels of NOx in brain tissues in comparison with sham-operated rats.
According to previous studies, the stimulation of 5HT 1A receptor led to downregulation of nNOS expression in the hippocampus. In addition, the knock-out of nNOS gene or use of 7-NI as a selective nNOS inhibitor, abolished anxiolytic effects of 8OH-DPAT or fluoxetine [25] . The authors suggested that nNOS was important in normal brain 5-HT function, especially in the 5HT 1A post synaptic receptor function [53] . Considering that 8OH-DPAT is a selective agonist of the 5HT 1A receptor, decreased level of NOx in 8OH-DPATtreated rats is conceivable. WAY100635 abolished the effect of 8OH-DPAT which confirmed the involvement of 5HT 1A receptor activation. In addition, the combination of sub-effective doses of L-NAME and sertraline further decreased NOx levels and the concomitant increase of seizure threshold. Thus, it seems that interaction Fig. 3 . The effect of the chronic L-NAME with 8-OH-DPAT or sertraline treatment on NO X concentration. NO X concentration was significantly reduced in pre-treatment with L-NAME in combination of 8-OH-DPAT and also this effect was observed during the treatment with L-NAME or 8-OH-DPAT alone. ***P < 0.001 and **P < 0.01 compared to vehicle group. {{{ P < 0.001 compared to 8-OH-DPAT. ^^^ P < 0.001 compared to L-NAME. ### P < 0.001 compared to sertraline.
between serotonergic and nitrergic system is to some extent responsible for the anticonvulsant effect of 8OH-DPAT.
Taking into account the inhibitory effect of 5HT 1A receptor agonists on nNOS, it is probable that combination of L-NAME with 8OH-DPAT augment the anticonvulsant effect of these two 5HT 1A receptor agonist. Although there are some reports that SSRIs diminish NO levels in the CNS, our results showed that sertraline did not significantly change NOx levels. Furthermore, Bahremand et al. have reported that combination of L-arginine with high doses of citalopram was mediated by 5HT3 receptor through increased activation of NOS [54] . In proof of this claim, the combination of sertraline with non-effective dose of L-NAME did not significantly change the seizure threshold or NOx levels.
Conclusions
During the last decade, many studies have indicated the important role of serotonin in seizure. According to the presented data, it seems that sertraline and 8OH-DPAT have anticonvulsant effect through the 5HT 1A receptors, although serotonin receptors other than 5HT 1A subtype may be involved. Furthermore, it is probable that some anticonvulsant effect of sertraline and 8OH-DPAT are through the modulation of nitrergic system.
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